Circulating Tumor Cell Market By Product (Kits & Reagents, Blood Collection Tubes, Devices) , By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection, CTC Analysis) By Application (Research, Clinical, Drug/Therapy Development) By Specimen

Published Sep 01, 2024

Length 280 Pages

SKU # ALMR19510365

Description

Circulating Tumor Cell Market By Product (Kits & Reagents, Blood Collection Tubes, Devices) , By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection, CTC Analysis) By Application (Research, Clinical, Drug/Therapy Development) By Specimen (Blood, Bone Marrow, Other Body Fluids) By End User (Hospital and Clinics, Diagnostic Centers, Research and Academic Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Circulating Tumor Cell Market

The circulating tumor cell market was valued at $11.8 billion in 2023 and is projected to reach $43.5 billion by 2033, growing at a CAGR of 13.9% from 2024 to 2033.

A circulating tumor cell (CTC) is a type of cell that detaches from the primary tumor and circulates into the whole body via bloodstream. CTCs are critical for enhancing treatment efficacy and improving patient outcomes as they are a precursor for metastatic cancer. They are heterogenous in nature as they vary in their phenotypic and genotypic characteristics.

Increase in the prevalence of different forms of cancer acts as a key driver of the circulating tumor cell market as it has fueled the demand for ingenious CTC diagnostic tools. In addition, innovations in liquid biopsy methods associated with CTC isolation and analysis propel the development of the market. The usage of nanotechnology & microfluidics for the extraction and detection of CTCs is a notable trend acquiring traction in the circulating tumor cell market. Nanoparticles enable precise targeting and capturing of CTCs owing to their engineered shape and surface properties.

However, lack of standardization in the extraction process leads to variations in results, hampering the development of the market. Moreover, stringent competition from alternative technologies such as circulating tumor DNA analysis restrains the market growth considerably. On the contrary, the assimilation of CTCs and personalized medicine is anticipated to present lucrative opportunities for the circulating tumor cell market. As per a recent research article published on the National Library of Medicine—the largest biomedical library globally—early detection and study of CTCs through single-cell techniques have the potential to personalize cancer treatment extensively for every patient. Study of CTCs at an early stage allows for identification of unique metastatic patterns in every patient, enabling precise targeting of damaged cells and healing of disease.

Segment Review

The circulating tumor cell market is segmented into product, technology, application, specimen, end user, and region. On the basis of product, the market is divided into kits & reagents, blood collection tubes, and devices. Depending on technology, it is classified into CTC detection & enrichment methods, CTC direct detection, and CTC analysis. As per application, it is categorized into research, clinical, and drug/therapy development. According to specimen, it is divided into blood, bone marrow, and other body fluids. By end user, it is classified into hospital & clinics, diagnostic centers, and research & academic institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product, the kits & reagents segment dominated the market in 2023.

Depending on technology, the CTC detection & enrichment methods segment acquired a high stake in the market in 2023.

As per application, the research segment was the highest shareholder in 2023.

According to specimen, the blood segment accounted for a high market share in 2023.

By end user, the research & academic institutes segment held a high share in the market in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players of the global circulating tumor cell market include Qiagen N.V., Bio-Techne Corporation, Precision for Medicine, Inc., AVIVA Biosciences, BioCEP Ltd., Fluxion Biosciences, Inc., Greiner Bio-One International GmbH, Ikonisys, Inc., Miltenyi Biotec GmbH, and IVDiagnostics, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Key Market Segments

By Product

Kits Reagents
Blood Collection Tubes
Devices

By Technology

CTC Detection Enrichment Methods
CTC Direct Detection
CTC Analysis

By Application

Research, Clinical
Drug/Therapy Development

By Specimen

Blood
Bone Marrow
Other Body Fluids

By End User

Hospital and Clinics
Diagnostic Centers
Research and Academic Institutes

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Qiagen NV.
Bio-Techne Corporation
Precision for Medicine, Inc.
AVIVA Biosciences
BioCEP Ltd
Fluxion Biosciences, Inc
Greiner Bio-One International GmbH
Ikonisys, Inc
Miltenyi Biotec GmbH.
IVDiagnostics, Inc

CHAPTER 1: INTRODUCTION: 1.1. Report Description; 1.2. Key Market Segments; 1.3. Key Benefits; 1.4. Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY: 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE: 3.1. Market Definition and Scope; 3.2. Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3. Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4. Market Dynamics; 3.4.1. Drivers; 3.4.2. Restraints; 3.4.3. Opportunities
CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY PRODUCT: 4.1. Market Overview; 4.1.1 Market Size and Forecast, By Product; 4.2. Kits Reagents; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Blood Collection Tubes; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country; 4.4. Devices; 4.4.1. Key Market Trends, Growth Factors and Opportunities; 4.4.2. Market Size and Forecast, By Region; 4.4.3. Market Share Analysis, By Country
CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY: 5.1. Market Overview; 5.1.1 Market Size and Forecast, By Technology; 5.2. CTC Detection Enrichment Methods; 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.2.2. Market Size and Forecast, By Region; 5.2.3. Market Share Analysis, By Country; 5.3. CTC Direct Detection; 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.3.2. Market Size and Forecast, By Region; 5.3.3. Market Share Analysis, By Country; 5.4. CTC Analysis; 5.4.1. Key Market Trends, Growth Factors and Opportunities; 5.4.2. Market Size and Forecast, By Region; 5.4.3. Market Share Analysis, By Country
CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY APPLICATION: 6.1. Market Overview; 6.1.1 Market Size and Forecast, By Application; 6.2. Research, Clinical; 6.2.1. Key Market Trends, Growth Factors and Opportunities; 6.2.2. Market Size and Forecast, By Region; 6.2.3. Market Share Analysis, By Country; 6.3. Drug/Therapy Development; 6.3.1. Key Market Trends, Growth Factors and Opportunities; 6.3.2. Market Size and Forecast, By Region; 6.3.3. Market Share Analysis, By Country
CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY SPECIMEN: 7.1. Market Overview; 7.1.1 Market Size and Forecast, By Specimen; 7.2. Blood; 7.2.1. Key Market Trends, Growth Factors and Opportunities; 7.2.2. Market Size and Forecast, By Region; 7.2.3. Market Share Analysis, By Country; 7.3. Bone Marrow; 7.3.1. Key Market Trends, Growth Factors and Opportunities; 7.3.2. Market Size and Forecast, By Region; 7.3.3. Market Share Analysis, By Country; 7.4. Other Body Fluids; 7.4.1. Key Market Trends, Growth Factors and Opportunities; 7.4.2. Market Size and Forecast, By Region; 7.4.3. Market Share Analysis, By Country
CHAPTER 8: CIRCULATING TUMOR CELL MARKET, BY END USER: 8.1. Market Overview; 8.1.1 Market Size and Forecast, By End User; 8.2. Hospital And Clinics; 8.2.1. Key Market Trends, Growth Factors and Opportunities; 8.2.2. Market Size and Forecast, By Region; 8.2.3. Market Share Analysis, By Country; 8.3. Diagnostic Centers; 8.3.1. Key Market Trends, Growth Factors and Opportunities; 8.3.2. Market Size and Forecast, By Region; 8.3.3. Market Share Analysis, By Country; 8.4. Research And Academic Institutes; 8.4.1. Key Market Trends, Growth Factors and Opportunities; 8.4.2. Market Size and Forecast, By Region; 8.4.3. Market Share Analysis, By Country
CHAPTER 9: CIRCULATING TUMOR CELL MARKET, BY REGION: 9.1. Market Overview; 9.1.1 Market Size and Forecast, By Region; 9.2. North America; 9.2.1. Key Market Trends and Opportunities; 9.2.2. Market Size and Forecast, By Product; 9.2.3. Market Size and Forecast, By Technology; 9.2.4. Market Size and Forecast, By Application; 9.2.5. Market Size and Forecast, By Specimen; 9.2.6. Market Size and Forecast, By End User; 9.2.7. Market Size and Forecast, By Country; 9.2.8. U.S. Circulating Tumor Cell Market; 9.2.8.1. Market Size and Forecast, By Product; 9.2.8.2. Market Size and Forecast, By Technology; 9.2.8.3. Market Size and Forecast, By Application; 9.2.8.4. Market Size and Forecast, By Specimen; 9.2.8.5. Market Size and Forecast, By End User; 9.2.9. Canada Circulating Tumor Cell Market; 9.2.9.1. Market Size and Forecast, By Product; 9.2.9.2. Market Size and Forecast, By Technology; 9.2.9.3. Market Size and Forecast, By Application; 9.2.9.4. Market Size and Forecast, By Specimen; 9.2.9.5. Market Size and Forecast, By End User; 9.2.10. Mexico Circulating Tumor Cell Market; 9.2.10.1. Market Size and Forecast, By Product; 9.2.10.2. Market Size and Forecast, By Technology; 9.2.10.3. Market Size and Forecast, By Application; 9.2.10.4. Market Size and Forecast, By Specimen; 9.2.10.5. Market Size and Forecast, By End User; 9.3. Europe; 9.3.1. Key Market Trends and Opportunities; 9.3.2. Market Size and Forecast, By Product; 9.3.3. Market Size and Forecast, By Technology; 9.3.4. Market Size and Forecast, By Application; 9.3.5. Market Size and Forecast, By Specimen; 9.3.6. Market Size and Forecast, By End User; 9.3.7. Market Size and Forecast, By Country; 9.3.8. Germany Circulating Tumor Cell Market; 9.3.8.1. Market Size and Forecast, By Product; 9.3.8.2. Market Size and Forecast, By Technology; 9.3.8.3. Market Size and Forecast, By Application; 9.3.8.4. Market Size and Forecast, By Specimen; 9.3.8.5. Market Size and Forecast, By End User; 9.3.9. France Circulating Tumor Cell Market; 9.3.9.1. Market Size and Forecast, By Product; 9.3.9.2. Market Size and Forecast, By Technology; 9.3.9.3. Market Size and Forecast, By Application; 9.3.9.4. Market Size and Forecast, By Specimen; 9.3.9.5. Market Size and Forecast, By End User; 9.3.10. UK Circulating Tumor Cell Market; 9.3.10.1. Market Size and Forecast, By Product; 9.3.10.2. Market Size and Forecast, By Technology; 9.3.10.3. Market Size and Forecast, By Application; 9.3.10.4. Market Size and Forecast, By Specimen; 9.3.10.5. Market Size and Forecast, By End User; 9.3.11. Italy Circulating Tumor Cell Market; 9.3.11.1. Market Size and Forecast, By Product; 9.3.11.2. Market Size and Forecast, By Technology; 9.3.11.3. Market Size and Forecast, By Application; 9.3.11.4. Market Size and Forecast, By Specimen; 9.3.11.5. Market Size and Forecast, By End User; 9.3.12. Spain Circulating Tumor Cell Market; 9.3.12.1. Market Size and Forecast, By Product; 9.3.12.2. Market Size and Forecast, By Technology; 9.3.12.3. Market Size and Forecast, By Application; 9.3.12.4. Market Size and Forecast, By Specimen; 9.3.12.5. Market Size and Forecast, By End User; 9.3.13. Rest Of Europe Circulating Tumor Cell Market; 9.3.13.1. Market Size and Forecast, By Product; 9.3.13.2. Market Size and Forecast, By Technology; 9.3.13.3. Market Size and Forecast, By Application; 9.3.13.4. Market Size and Forecast, By Specimen; 9.3.13.5. Market Size and Forecast, By End User; 9.4. Asia-Pacific; 9.4.1. Key Market Trends and Opportunities; 9.4.2. Market Size and Forecast, By Product; 9.4.3. Market Size and Forecast, By Technology; 9.4.4. Market Size and Forecast, By Application; 9.4.5. Market Size and Forecast, By Specimen; 9.4.6. Market Size and Forecast, By End User; 9.4.7. Market Size and Forecast, By Country; 9.4.8. Japan Circulating Tumor Cell Market; 9.4.8.1. Market Size and Forecast, By Product; 9.4.8.2. Market Size and Forecast, By Technology; 9.4.8.3. Market Size and Forecast, By Application; 9.4.8.4. Market Size and Forecast, By Specimen; 9.4.8.5. Market Size and Forecast, By End User; 9.4.9. China Circulating Tumor Cell Market; 9.4.9.1. Market Size and Forecast, By Product; 9.4.9.2. Market Size and Forecast, By Technology; 9.4.9.3. Market Size and Forecast, By Application; 9.4.9.4. Market Size and Forecast, By Specimen; 9.4.9.5. Market Size and Forecast, By End User; 9.4.10. Australia Circulating Tumor Cell Market; 9.4.10.1. Market Size and Forecast, By Product; 9.4.10.2. Market Size and Forecast, By Technology; 9.4.10.3. Market Size and Forecast, By Application; 9.4.10.4. Market Size and Forecast, By Specimen; 9.4.10.5. Market Size and Forecast, By End User; 9.4.11. India Circulating Tumor Cell Market; 9.4.11.1. Market Size and Forecast, By Product; 9.4.11.2. Market Size and Forecast, By Technology; 9.4.11.3. Market Size and Forecast, By Application; 9.4.11.4. Market Size and Forecast, By Specimen; 9.4.11.5. Market Size and Forecast, By End User; 9.4.12. South Korea Circulating Tumor Cell Market; 9.4.12.1. Market Size and Forecast, By Product; 9.4.12.2. Market Size and Forecast, By Technology; 9.4.12.3. Market Size and Forecast, By Application; 9.4.12.4. Market Size and Forecast, By Specimen; 9.4.12.5. Market Size and Forecast, By End User; 9.4.13. Rest of Asia-Pacific Circulating Tumor Cell Market; 9.4.13.1. Market Size and Forecast, By Product; 9.4.13.2. Market Size and Forecast, By Technology; 9.4.13.3. Market Size and Forecast, By Application; 9.4.13.4. Market Size and Forecast, By Specimen; 9.4.13.5. Market Size and Forecast, By End User; 9.5. LAMEA; 9.5.1. Key Market Trends and Opportunities; 9.5.2. Market Size and Forecast, By Product; 9.5.3. Market Size and Forecast, By Technology; 9.5.4. Market Size and Forecast, By Application; 9.5.5. Market Size and Forecast, By Specimen; 9.5.6. Market Size and Forecast, By End User; 9.5.7. Market Size and Forecast, By Country; 9.5.8. Brazil Circulating Tumor Cell Market; 9.5.8.1. Market Size and Forecast, By Product; 9.5.8.2. Market Size and Forecast, By Technology; 9.5.8.3. Market Size and Forecast, By Application; 9.5.8.4. Market Size and Forecast, By Specimen; 9.5.8.5. Market Size and Forecast, By End User; 9.5.9. Saudi Arabia Circulating Tumor Cell Market; 9.5.9.1. Market Size and Forecast, By Product; 9.5.9.2. Market Size and Forecast, By Technology; 9.5.9.3. Market Size and Forecast, By Application; 9.5.9.4. Market Size and Forecast, By Specimen; 9.5.9.5. Market Size and Forecast, By End User; 9.5.10. South Africa Circulating Tumor Cell Market; 9.5.10.1. Market Size and Forecast, By Product; 9.5.10.2. Market Size and Forecast, By Technology; 9.5.10.3. Market Size and Forecast, By Application; 9.5.10.4. Market Size and Forecast, By Specimen; 9.5.10.5. Market Size and Forecast, By End User; 9.5.11. Rest of LAMEA Circulating Tumor Cell Market; 9.5.11.1. Market Size and Forecast, By Product; 9.5.11.2. Market Size and Forecast, By Technology; 9.5.11.3. Market Size and Forecast, By Application; 9.5.11.4. Market Size and Forecast, By Specimen; 9.5.11.5. Market Size and Forecast, By End User
CHAPTER 10: COMPETITIVE LANDSCAPE: 10.1. Introduction; 10.2. Top Winning Strategies; 10.3. Product Mapping Of Top 10 Player; 10.4. Competitive Dashboard; 10.5. Competitive Heatmap; 10.6. Top Player Positioning, 2023
CHAPTER 11: COMPANY PROFILES: 11.1. Qiagen NV.; 11.1.1. Company Overview; 11.1.2. Key Executives; 11.1.3. Company Snapshot; 11.1.4. Operating Business Segments; 11.1.5. Product Portfolio; 11.1.6. Business Performance; 11.1.7. Key Strategic Moves and Developments; 11.2. Bio-Techne Corporation; 11.2.1. Company Overview; 11.2.2. Key Executives; 11.2.3. Company Snapshot; 11.2.4. Operating Business Segments; 11.2.5. Product Portfolio; 11.2.6. Business Performance; 11.2.7. Key Strategic Moves and Developments; 11.3. Precision For Medicine, Inc.; 11.3.1. Company Overview; 11.3.2. Key Executives; 11.3.3. Company Snapshot; 11.3.4. Operating Business Segments; 11.3.5. Product Portfolio; 11.3.6. Business Performance; 11.3.7. Key Strategic Moves and Developments; 11.4. AVIVA Biosciences; 11.4.1. Company Overview; 11.4.2. Key Executives; 11.4.3. Company Snapshot; 11.4.4. Operating Business Segments; 11.4.5. Product Portfolio; 11.4.6. Business Performance; 11.4.7. Key Strategic Moves and Developments; 11.5. BioCEP Ltd; 11.5.1. Company Overview; 11.5.2. Key Executives; 11.5.3. Company Snapshot; 11.5.4. Operating Business Segments; 11.5.5. Product Portfolio; 11.5.6. Business Performance; 11.5.7. Key Strategic Moves and Developments; 11.6. Fluxion Biosciences, Inc; 11.6.1. Company Overview; 11.6.2. Key Executives; 11.6.3. Company Snapshot; 11.6.4. Operating Business Segments; 11.6.5. Product Portfolio; 11.6.6. Business Performance; 11.6.7. Key Strategic Moves and Developments; 11.7. Greiner Bio-One International GmbH; 11.7.1. Company Overview; 11.7.2. Key Executives; 11.7.3. Company Snapshot; 11.7.4. Operating Business Segments; 11.7.5. Product Portfolio; 11.7.6. Business Performance; 11.7.7. Key Strategic Moves and Developments; 11.8. Ikonisys, Inc; 11.8.1. Company Overview; 11.8.2. Key Executives; 11.8.3. Company Snapshot; 11.8.4. Operating Business Segments; 11.8.5. Product Portfolio; 11.8.6. Business Performance; 11.8.7. Key Strategic Moves and Developments; 11.9. Miltenyi Biotec GmbH.; 11.9.1. Company Overview; 11.9.2. Key Executives; 11.9.3. Company Snapshot; 11.9.4. Operating Business Segments; 11.9.5. Product Portfolio; 11.9.6. Business Performance; 11.9.7. Key Strategic Moves and Developments; 11.10. IVDiagnostics, Inc; 11.10.1. Company Overview; 11.10.2. Key Executives; 11.10.3. Company Snapshot; 11.10.4. Operating Business Segments; 11.10.5. Product Portfolio; 11.10.6. Business Performance; 11.10.7. Key Strategic Moves and Developments
LIST OF TABLES: TABLE 1. GLOBAL CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 2. CIRCULATING TUMOR CELL MARKET FOR KITS REAGENTS, BY REGION, 2024 - 2033 ($BILLION); TABLE 3. CIRCULATING TUMOR CELL MARKET FOR BLOOD COLLECTION TUBES, BY REGION, 2024 - 2033 ($BILLION); TABLE 4. CIRCULATING TUMOR CELL MARKET FOR DEVICES, BY REGION, 2024 - 2033 ($BILLION); TABLE 5. GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 6. CIRCULATING TUMOR CELL MARKET FOR CTC DETECTION ENRICHMENT METHODS, BY REGION, 2024 - 2033 ($BILLION); TABLE 7. CIRCULATING TUMOR CELL MARKET FOR CTC DIRECT DETECTION, BY REGION, 2024 - 2033 ($BILLION); TABLE 8. CIRCULATING TUMOR CELL MARKET FOR CTC ANALYSIS, BY REGION, 2024 - 2033 ($BILLION); TABLE 9. GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 10. CIRCULATING TUMOR CELL MARKET FOR RESEARCH, CLINICAL, BY REGION, 2024 - 2033 ($BILLION); TABLE 11. CIRCULATING TUMOR CELL MARKET FOR DRUG/THERAPY DEVELOPMENT, BY REGION, 2024 - 2033 ($BILLION); TABLE 12. GLOBAL CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 13. CIRCULATING TUMOR CELL MARKET FOR BLOOD, BY REGION, 2024 - 2033 ($BILLION); TABLE 14. CIRCULATING TUMOR CELL MARKET FOR BONE MARROW, BY REGION, 2024 - 2033 ($BILLION); TABLE 15. CIRCULATING TUMOR CELL MARKET FOR OTHER BODY FLUIDS, BY REGION, 2024 - 2033 ($BILLION); TABLE 16. GLOBAL CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 17. CIRCULATING TUMOR CELL MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2024 - 2033 ($BILLION); TABLE 18. CIRCULATING TUMOR CELL MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2024 - 2033 ($BILLION); TABLE 19. CIRCULATING TUMOR CELL MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2024 - 2033 ($BILLION); TABLE 20. CIRCULATING TUMOR CELL MARKET, BY REGION, 2024 - 2033 ($BILLION); TABLE 21. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 22. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 23. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 24. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 25. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 26. NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 27. U.S. CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 28. U.S. CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 29. U.S. CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 30. U.S. CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 31. U.S. CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 32. CANADA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 33. CANADA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 34. CANADA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 35. CANADA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 36. CANADA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 37. MEXICO CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 38. MEXICO CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 39. MEXICO CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 40. MEXICO CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 41. MEXICO CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 42. EUROPE CIRCULATING TUMOR CELL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 43. EUROPE CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 44. EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 45. EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 46. EUROPE CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 47. EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 48. GERMANY CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 49. GERMANY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 50. GERMANY CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 51. GERMANY CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 52. GERMANY CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 53. FRANCE CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 54. FRANCE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 55. FRANCE CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 56. FRANCE CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 57. FRANCE CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 58. UK CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 59. UK CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 60. UK CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 61. UK CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 62. UK CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 63. ITALY CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 64. ITALY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 65. ITALY CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 66. ITALY CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 67. ITALY CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 68. SPAIN CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 69. SPAIN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 70. SPAIN CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 71. SPAIN CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 72. SPAIN CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 73. REST OF EUROPE CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 74. REST OF EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 75. REST OF EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 76. REST OF EUROPE CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 77. REST OF EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 78. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 79. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 80. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 81. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 82. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 83. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 84. JAPAN CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 85. JAPAN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 86. JAPAN CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 87. JAPAN CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 88. JAPAN CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 89. CHINA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 90. CHINA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 91. CHINA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 92. CHINA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 93. CHINA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 94. AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 95. AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 96. AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 97. AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 98. AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 99. INDIA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 100. INDIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 101. INDIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 102. INDIA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 103. INDIA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 104. SOUTH KOREA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 105. SOUTH KOREA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 106. SOUTH KOREA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 107. SOUTH KOREA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 108. SOUTH KOREA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 109. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 110. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 111. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 112. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 113. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 114. LAMEA CIRCULATING TUMOR CELL MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 115. LAMEA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 116. LAMEA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 117. LAMEA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 118. LAMEA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 119. LAMEA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 120. BRAZIL CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 121. BRAZIL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 122. BRAZIL CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 123. BRAZIL CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 124. BRAZIL CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 125. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 126. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 127. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 128. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 129. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 130. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 131. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 132. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 133. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 134. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 135. REST OF LAMEA CIRCULATING TUMOR CELL MARKET, BY PRODUCT, 2024 - 2033 ($BILLION); TABLE 136. REST OF LAMEA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION); TABLE 137. REST OF LAMEA CIRCULATING TUMOR CELL MARKET, BY APPLICATION, 2024 - 2033 ($BILLION); TABLE 138. REST OF LAMEA CIRCULATING TUMOR CELL MARKET, BY SPECIMEN, 2024 - 2033 ($BILLION); TABLE 139. REST OF LAMEA CIRCULATING TUMOR CELL MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 140. QIAGEN NV.: KEY EXECUTIVES; TABLE 141. QIAGEN NV.: COMPANY SNAPSHOT; TABLE 142. QIAGEN NV.: OPERATING SEGMENTS; TABLE 143. QIAGEN NV.: PRODUCT PORTFOLIO; TABLE 144. QIAGEN NV.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 145. BIO-TECHNE CORPORATION: KEY EXECUTIVES; TABLE 146. BIO-TECHNE CORPORATION: COMPANY SNAPSHOT; TABLE 147. BIO-TECHNE CORPORATION: OPERATING SEGMENTS; TABLE 148. BIO-TECHNE CORPORATION: PRODUCT PORTFOLIO; TABLE 149. BIO-TECHNE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 150. PRECISION FOR MEDICINE, INC.: KEY EXECUTIVES; TABLE 151. PRECISION FOR MEDICINE, INC.: COMPANY SNAPSHOT; TABLE 152. PRECISION FOR MEDICINE, INC.: OPERATING SEGMENTS; TABLE 153. PRECISION FOR MEDICINE, INC.: PRODUCT PORTFOLIO; TABLE 154. PRECISION FOR MEDICINE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 155. AVIVA BIOSCIENCES: KEY EXECUTIVES; TABLE 156. AVIVA BIOSCIENCES: COMPANY SNAPSHOT; TABLE 157. AVIVA BIOSCIENCES: OPERATING SEGMENTS; TABLE 158. AVIVA BIOSCIENCES: PRODUCT PORTFOLIO; TABLE 159. AVIVA BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 160. BIOCEP LTD: KEY EXECUTIVES; TABLE 161. BIOCEP LTD: COMPANY SNAPSHOT; TABLE 162. BIOCEP LTD: OPERATING SEGMENTS; TABLE 163. BIOCEP LTD: PRODUCT PORTFOLIO; TABLE 164. BIOCEP LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 165. FLUXION BIOSCIENCES, INC: KEY EXECUTIVES; TABLE 166. FLUXION BIOSCIENCES, INC: COMPANY SNAPSHOT; TABLE 167. FLUXION BIOSCIENCES, INC: OPERATING SEGMENTS; TABLE 168. FLUXION BIOSCIENCES, INC: PRODUCT PORTFOLIO; TABLE 169. FLUXION BIOSCIENCES, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 170. GREINER BIO-ONE INTERNATIONAL GMBH: KEY EXECUTIVES; TABLE 171. GREINER BIO-ONE INTERNATIONAL GMBH: COMPANY SNAPSHOT; TABLE 172. GREINER BIO-ONE INTERNATIONAL GMBH: OPERATING SEGMENTS; TABLE 173. GREINER BIO-ONE INTERNATIONAL GMBH: PRODUCT PORTFOLIO; TABLE 174. GREINER BIO-ONE INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 175. IKONISYS, INC: KEY EXECUTIVES; TABLE 176. IKONISYS, INC: COMPANY SNAPSHOT; TABLE 177. IKONISYS, INC: OPERATING SEGMENTS; TABLE 178. IKONISYS, INC: PRODUCT PORTFOLIO; TABLE 179. IKONISYS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 180. MILTENYI BIOTEC GMBH.: KEY EXECUTIVES; TABLE 181. MILTENYI BIOTEC GMBH.: COMPANY SNAPSHOT; TABLE 182. MILTENYI BIOTEC GMBH.: OPERATING SEGMENTS; TABLE 183. MILTENYI BIOTEC GMBH.: PRODUCT PORTFOLIO; TABLE 184. MILTENYI BIOTEC GMBH.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 185. IVDIAGNOSTICS, INC: KEY EXECUTIVES; TABLE 186. IVDIAGNOSTICS, INC: COMPANY SNAPSHOT; TABLE 187. IVDIAGNOSTICS, INC: OPERATING SEGMENTS; TABLE 188. IVDIAGNOSTICS, INC: PRODUCT PORTFOLIO; TABLE 189. IVDIAGNOSTICS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1. GLOBAL CIRCULATING TUMOR CELL MARKET, 2024 - 2033; FIGURE 2. SEGMENTATION OF CIRCULATING TUMOR CELL MARKET, 2024 - 2033; FIGURE 3. TOP INVESTMENT POCKET IN CIRCULATING TUMOR CELL MARKET; FIGURE 4. MODERATE BARGAINING POWER OF BUYERS; FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS

Pricing

Currency Rates

Single User Email from Publisher $4,425
Global Site License Email from Publisher $7,412

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now